Gout
Red Flags — act before continuing history
| Red flag | Why dangerous | Action |
|---|---|---|
| Hot swollen joint + fever (>38°C) + systemically unwell | Septic arthritis is the most feared mimic of gout and is a surgical emergency. Delay to diagnosis and joint washout risks permanent joint destruction, osteomyelitis, and septicaemia. Gout and septic arthritis can coexist in the same joint. Fever does not exclude gout but cannot exclude septic arthritis — joint aspiration is the only way to differentiate. | Same-day joint aspiration + orthopaedics/rheumatology |
| Hot swollen joint in an immunosuppressed patient (transplant, steroids, biological agents, chemotherapy) | Immunosuppressed patients have dramatically higher risk of septic arthritis from organisms that would not cause joint infection in immunocompetent hosts. The usual systemic inflammatory response may be blunted, making clinical distinction from gout even harder. Do not rely on typical gout features in this population. | Same-day joint aspiration + infectious disease / orthopaedics |
| Rapidly spreading cellulitis or erythema beyond the joint | Cellulitis complicating or mimicking gout can be misdiagnosed as the joint inflammation of gout itself. Spreading cellulitis with a red line (lymphangitis) or rapidly expanding erythema indicates bacterial soft tissue infection requiring IV antibiotics and inpatient admission. The risk of necrotising fasciitis exists in severe cases. | Same-day A&E if lymphangitis or rapidly spreading |
| Signs of systemic sepsis with joint inflammation (tachycardia, hypotension, confusion) | Septic arthritis causing haematogenous spread can progress to frank sepsis with haemodynamic compromise. Any patient with a hot joint and cardiovascular or neurological compromise needs emergency assessment and likely IV antibiotics. | 999 / A&E immediately |
| First presentation of hot joint in a child or young adult (<30 years) | Primary gout is extremely rare in pre-menopausal women or men under 30. A hot swollen joint in this age group should prompt consideration of: septic arthritis, reactive arthritis (sexually acquired — Chlamydia), haemophilia or other haematological cause, pseudogout (CPPD), or secondary gout from an underlying metabolic disease (enzyme deficiency, lymphoproliferative disorder). Screen for STIs if sexually active and young. | Urgent investigation; STI screen if young adult; rheumatology referral |
| Rapidly progressive polyarthritis with systemic features | Acute polyarticular flare with fever and systemic symptoms may represent acute rheumatoid arthritis presenting as a flare, viral arthritis (parvovirus B19, hepatitis B), reactive arthritis, or very rarely Still's disease. These all require urgent specialist assessment. | Urgent rheumatology referral within 2 weeks |
Safeguarding Considerations — Consider in Every Consultation
🍺 Alcohol Use and Dependence
- Quantify alcohol intake using AUDIT-C at every gout consultation
- Heavy alcohol use is the strongest modifiable risk factor for gout recurrence
- Alcohol dependence may indicate neglect of dependent children or vulnerable adults
- Brief intervention for hazardous drinking (FRAMES) appropriate; refer to drug and alcohol service if dependent
🏠 Domestic Abuse and Social Circumstances
- Recurrent gout flares without compliance with management may reflect social adversity, inability to afford healthy food, or unsafe living conditions
- If injuries noted alongside joint presentation, consider whether trauma has been disclosed accurately
- Patients presenting repeatedly in crisis without engaging with long-term management — consider whether there are social barriers to engagement
👴 Older Adults and Frailty
- Gout in a frail older adult may represent polypharmacy-driven hyperuricaemia (multiple diuretics, low-dose aspirin)
- Severe gout pain in an older adult with limited mobility may indicate carer stress or inability to manage at home
- Review social support and carer capacity when managing severe acute gout in frail patients
💊 Medication Concerns and Self-Harm
- Patients requesting large supplies of colchicine — note that colchicine is highly toxic in overdose (multi-organ failure)
- Be aware of suicide risk in the context of chronic pain and depression — gout and recurrent flares may worsen mood significantly
- Medication misuse risk: colchicine toxicity is potentially fatal at relatively small overdoses
🍺 Alcohol Culture and Social Context
Alcohol consumption — particularly beer — is the most powerful modifiable risk factor for gout recurrence. For many patients, drinking is deeply embedded in their social identity, occupational culture (building trades, agriculture, hospitality), or is a coping mechanism for stress.
"I can see that cutting down on beer would be a significant change — can you tell me a bit about how central that is to your social life and work, so I can understand what would actually be realistic for you?"Non-judgmental quantification and brief motivational intervention; link alcohol reduction directly to reduced flare frequency as a motivational frame.
🍽️ Diet and Food Access
Dietary modification for gout requires access to affordable low-purine protein sources. Advice to "reduce red meat and eat more fish" can be economically challenging for patients in food poverty. Shellfish, offal, and processed meat may form a significant proportion of a patient's diet for financial reasons.
"We've talked about some dietary changes — I want to make sure the advice I'm giving you is actually achievable with your shopping budget and cooking situation. Is there anything that might make it difficult to follow?"Social prescribing referral if food access is a barrier; dietitian referral for complex dietary management; avoid victim-blaming framing.
😤 Stigma and Self-Blame
Gout carries a significant cultural stigma — it has historically been characterised as a disease of gluttony and excess. Many patients feel deeply embarrassed and blame themselves entirely for the condition. This shame delays presentation, reduces adherence, and prevents open discussion of the lifestyle factors contributing to the disease.
"I want to say clearly that gout is a medical condition, not a moral failing. There are genetic and physiological factors at play, not just lifestyle. Plenty of people who live very healthily still get gout."Destigmatising gout explicitly improves treatment adherence and patient engagement. Normalising the condition as metabolic rather than moral changes the therapeutic relationship.
💼 Occupational Impact and Sick Leave
Acute gout flares can be severely disabling — patients who work in manual occupations (construction, driving, agriculture) may be unable to work during a flare. For self-employed patients, inability to work has direct financial consequences. Chronic tophaceous gout can cause permanent disability.
"This attack sounds like it's affecting your ability to work — is that something we need to think about? I can provide a fit note if you need time off to manage this."Fit note appropriate for severe acute gout; framing ULT as "preventing future episodes that stop you working" is a powerful motivational tool for occupationally active patients.
⚕️ Medication Reluctance and Health Beliefs
Patients with gout frequently refuse or discontinue allopurinol because of fears about long-term medication use, concerns about the initial flare-triggering effect of ULT, or online misinformation about side effects. This is the primary reason gout remains poorly controlled in the majority of patients.
"A lot of people worry about taking a tablet every day for life, or have read things online about allopurinol. Can I tell you what the evidence actually says — including the bit about it sometimes causing a flare at the start, which is real but preventable?"Address the allopurinol-flare concern explicitly and proactively — this is the single most important factor in improving adherence. Co-prescribe colchicine prophylaxis when starting ULT.
🏃 Physical Activity and Weight
Obesity significantly raises serum urate via increased purine synthesis. Weight loss reduces both serum urate and flare frequency. However, rapid weight loss (crash dieting, bariatric surgery) can paradoxically precipitate gout flares by mobilising urate from tissue stores. Exercise itself rarely triggers gout but dehydration during exercise does.
"Losing weight gradually would genuinely help reduce these attacks — but very rapid weight loss can actually trigger a flare temporarily, so we'd want to take a sustainable approach rather than a crash diet."Recommend gradual weight loss (<1kg/week); physical activity should be encouraged but with adequate hydration; exercise referral scheme if available.
- Not asking about systemic features (fever, rigors) — missing septic arthritis
- Not reviewing medications for urate-raising drugs (diuretics, aspirin)
- Not quantifying number of previous episodes (determines ULT eligibility)
- Ignoring alcohol history as a modifiable trigger
- Not asking about tophi or kidney stones (NICE NG219 ULT criteria)
- Diagnosing gout without at least considering and excluding septic arthritis
Same-Day Hospital / Orthopaedics
Act immediately- Hot swollen joint + fever (>38°C) + systemically unwellSeptic arthritis until proven otherwise → same-day joint aspiration + orthopaedics / rheumatology
- Immunosuppressed patient + acute hot joint (transplant, biologics, chemotherapy, steroids)Cannot clinically exclude septic arthritis → same-day aspiration regardless of prior gout history
- Suspected sepsis with joint inflammation (HR >90, hypotension, confusion)Emergency 999 / A&E — IV antibiotics, joint aspiration, haemodynamic resuscitation
- Rapidly spreading cellulitis with lymphangitisRisk of necrotising fasciitis → same-day A&E + IV antibiotics
- Acute urate nephropathy (severe gout + acute kidney injury signs)Tumour lysis / massive hyperuricaemia → urgent renal assessment
Same-Day / 2-Week Assessment
Urgent investigation- First episode of acute joint inflammation without prior diagnosisSerum urate, FBC, renal function, CRP same-day; arrange joint aspiration if diagnosis uncertain
- Polyarticular acute gout — first presentationRheumatology referral within 2 weeks; consider reactive arthritis, RA, or pseudogout in DDx
- Gout with AKI or rapidly worsening CKDUrgent renal function + urine dipstick; nephrology if AKI; allopurinol dose review
- Severe tophaceous gout with ulceration or infection of tophusRisk of secondary infection; wound management + antibiotics if infected; rheumatology for complex ULT
- Suspected haematological cause (very young, very high urate, cytopenias)FBC + haematology referral if lymphoma or polycythaemia suspected
Manage in Primary Care
GP practice- Acute gout flare — known diagnosis, afebrile, immunocompetentColchicine or NSAID for acute attack; serum urate after flare settles; review ULT eligibility
- Recurrent gout — initiating ULTStart allopurinol 50–100mg OD with colchicine prophylaxis; 4-weekly titration; lifestyle review
- Review of established allopurinol / monitoringSerum urate (target ≤360 µmol/L); renal function + FBC annually; dose adjustment if not at target
- Medication review — thiazide for hypertensionSwitch to losartan ARB (mild uricosuric); review all urate-raising medications
- Assuming gout without at least asking about fever and systemic illness
- Not explaining to the patient why septic arthritis exclusion matters
- Missing the immunosuppressed patient who requires same-day aspiration
- Sending a febrile patient with a hot swollen joint home with colchicine alone
- Not taking temperature — the most important examination finding in acute gout
- Not checking for tophi — misses a NICE NG219 ULT criterion
- Not examining blood pressure if thiazide is prescribed
- Not communicating examination findings to patient
- Diagnosing gout based on a "normal uric acid" during an acute flare — serum urate can be normal during acute inflammation
- Not checking renal function before prescribing allopurinol
- Not explaining to the patient why investigations are being requested
- Using a normal serum urate to confidently exclude gout
"What is happening in your joint is this: a chemical in your blood called uric acid has built up to a higher level than your body can handle. When the level gets high enough, tiny sharp crystals — like microscopic needles — form in the joint fluid. Those crystals cause an intense inflammatory reaction in the joint — which is why the pain comes on so rapidly and is so extreme. It's those crystals that are causing the redness, the swelling, and the agony. The good news is that if we can bring your uric acid level down and keep it down, the crystals dissolve away over time and the attacks stop. The medication we use for this — allopurinol — has been used safely for over 60 years and is very effective."
"My wife says it's because I eat too much rich food — I just need to change my diet."
"Diet does play a role, and we'll definitely talk about some dietary changes that help. But I want to be honest with you: diet alone usually isn't enough to bring uric acid levels down to where they need to be. Most people with gout need medication alongside dietary changes. The good news is that the medication is straightforward, well-tolerated, and once your levels are stable, you should stop getting these attacks."
"My friend said allopurinol actually caused his gout to flare up — so I don't want to take it."
"Your friend is right that when you first start allopurinol, it can sometimes trigger a flare in the first few weeks — and I need to explain why, because it's important. When the allopurinol starts working and uric acid levels drop, crystals that are already in the joint can shift, and that movement can cause a temporary flare. It's actually a sign the treatment is working. We prevent this by prescribing a low-dose anti-inflammatory alongside the allopurinol for the first six months. Once you're established on it, it shouldn't happen."
Acute gout (podagra / articular) — Classic nocturnal onset, exquisite tenderness, erythema, swelling of first MTP joint. Elevated urate (4–6 weeks after flare). Responds to colchicine or NSAIDs within 24–48 hours.
Chronic tophaceous gout — Recurrent flares, tophi on examination, elevated serum urate, ULT criteria met. NICE NG219 target urate ≤300 µmol/L.
Pseudogout (CPPD — calcium pyrophosphate deposition) — Often affects the knee; older patients; calcium deposits visible on X-ray. Managed similarly to gout acutely (NSAIDs, colchicine); no long-term ULT equivalent.
Psoriatic Arthritis
Inflammatory arthritis affecting similar joints to gout (DIP joints, first MTP); psoriasis or nail pitting present; may have elevated urate as comorbidity but requires methotrexate / biologics — not ULT alone.
Reactive Arthritis (Sexually Acquired)
Young adult, recent urethritis or GI infection, asymmetric oligoarthritis; Chlamydia or enteric organisms. STI screen, urethral swab, GI cultures. Managed with NSAIDs and treatment of underlying infection.
Early Rheumatoid Arthritis
Symmetrical small joint arthritis, morning stiffness, RF/anti-CCP positive; joint space loss on X-ray. Requires urgent rheumatology referral within 2 weeks for DMARDs.
Septic Arthritis
Hot swollen joint + fever + systemic illness → same-day joint aspiration. Staphylococcus aureus most common. IV antibiotics + joint washout. Permanent joint destruction if delayed >24h. Gout and septic arthritis can coexist.
Acute Urate Nephropathy (Tumour Lysis)
Massive hyperuricaemia from cell lysis (haematological malignancy treatment) → acute renal failure. Emergency IV fluids + rasburicase (uric acid oxidase) + urgent nephrology and oncology.
- Telling the patient that diet alone will cure gout — clinically inaccurate for most patients
- Not explaining the crystal mechanism — patients who don't understand the mechanism won't adhere to ULT
- Not addressing the allopurinol-flare concern proactively — this is the most common reason for ULT non-adherence
- Not distinguishing gout from septic arthritis in the explanation
- Not referring a febrile patient with a hot joint for joint aspiration
- Starting allopurinol in a patient on azathioprine without specialist input
- Not explaining to the patient why hospital referral is needed
- Using febuxostat in a patient with established CVD without discussing the MHRA safety update
Validate — name their expectation
The patient with an acute flare has one priority: stop this agonising pain today. The conversation about long-term ULT, diet, and lifestyle is entirely secondary to that need. Acknowledging the severity of the pain and the urgency of the relief request is both empathetic and therapeutically necessary — it creates the alliance needed for the longer discussion.
"I completely understand — this pain is severe, and dealing with it is absolutely the first priority. Let's start there and then I'll explain what we can do to stop this happening again."Explain — share your clinical reasoning
The patient needs to understand why the acute treatment (colchicine) and the long-term treatment (allopurinol) are different things that serve different purposes. Without this explanation, they will conflate them, take the colchicine long-term, and refuse allopurinol as "too many tablets."
"The tablet I'm giving you now — colchicine — will calm the inflammation and stop this attack. Then, once it's settled, I want to talk about a different medication that actually lowers your uric acid level to prevent these attacks from happening at all."Negotiate — offer something today
The acute attack requires immediate prescription. If ULT is indicated, plant the seed today and arrange a follow-up in 4–6 weeks once the flare has settled to initiate allopurinol. Never start allopurinol during an acute flare — explain why. Give the patient written information about gout to read while they recover.
"Today I'll prescribe you the colchicine to stop this attack. Once you're feeling better — usually about 4–6 weeks — I'd like to see you back to start you on the long-term medication. In the meantime, here's a leaflet that explains everything we've discussed today."Beer is doubly goutogenic: high purine content directly raises urate, and ethanol inhibits renal urate excretion. Even a single heavy drinking episode acutely raises serum urate significantly. Wine has a weaker effect on urate than beer or spirits. Alcohol also causes dehydration, further concentrating urate.
AUDIT-C at every gout consultation. Switch from beer to wine if alcohol is consumed. Avoid beer entirely during a flare or when starting ULT. Set a weekly unit limit and track it. Brief intervention using motivational interviewing. Drug and alcohol service if dependent.
High-purine foods (red meat, organ meats, shellfish, anchovies, sardines) directly raise serum urate as purines are metabolised to uric acid. Low-fat dairy products (milk, yoghurt) are uricosuric — they increase renal urate excretion. Fructose-sweetened drinks (fruit juice, fizzy drinks) raise urate via hepatic fructose metabolism independently of purine content.
Reduce red meat to 2–3 portions/week maximum; replace with chicken, turkey, tofu, eggs, low-fat dairy. Eliminate organ meats (liver, kidney, sweetbreads) and anchovies. Switch fizzy drinks and fruit juice to water. 1–2 portions low-fat dairy per day. Cherries and cherry extract may have modest benefit (controversial evidence).
Adequate hydration maintains renal urate excretion and prevents urate from concentrating in the distal tubule and joints. Dehydration — even mild — is a common precipitant of acute gout attacks, particularly during hot weather, exercise, or intercurrent illness. Uric acid is more soluble in dilute urine.
Aim for 2–3 litres of water daily. Increase intake during exercise, hot weather, or illness. Alkaline water or sodium bicarbonate supplementation can reduce uric acid stone formation (specialist indication). Avoid dehydrating beverages (alcohol, caffeine) as primary fluid source.
Obesity increases serum urate via increased purine synthesis and insulin resistance reducing renal urate excretion. Each BMI unit reduction is associated with a meaningful reduction in serum urate. However, rapid weight loss paradoxically mobilises urate from tissue stores and can precipitate acute flares — gradual loss is essential.
Target gradual weight loss (0.5–1 kg/week) rather than crash dieting. Exercise should be encouraged but with adequate hydration. Exercise referral scheme if available. Weight loss of 10kg in obese patients can reduce serum urate by 60–100 µmol/L. Bariatric surgery: associated with transient gout worsening post-operatively.
Thiazide and loop diuretics are among the most common iatrogenic causes of gout in primary care. Losartan (ARB) has a mild uricosuric effect — it reduces serum urate by approximately 15–20% and provides equivalent antihypertensive efficacy to thiazides. Low-dose aspirin raises urate and cannot be stopped if cardiovascular indication exists.
For patients on bendroflumethiazide or indapamide for uncomplicated hypertension: switch to losartan 50mg OD (titrate to 100mg if needed). Monitor BP and renal function (eGFR, K+) 4–6 weeks after switch. Do not switch loop diuretics in heart failure patients. Low-dose aspirin: do not stop for gout.
Low-fat dairy products are uricosuric via casein and lactalbumin effects on renal urate handling. Coffee (caffeinated) has been associated with lower urate levels in epidemiological studies — mechanism unclear. Cherries and cherry extract have modest anti-inflammatory and modest urate-lowering effects in small studies. Vitamin C supplementation has a small uricosuric effect.
2 portions low-fat milk or yoghurt daily. Coffee intake not restricted (unless cardiovascular concern). Cherry juice: 240ml/day may reduce flare frequency modestly. Vitamin C 500mg OD — small but meaningful uricosuric effect. These are supplements to medication, not replacements.
Colchicine 500mcg BD–TDS — start as early as possible in the attack (within 12 hours is optimal). Maximum 6mg per course. Start with lower frequency (BD or TDS) rather than the old high-loading dose regimen which caused significant GI toxicity.
- NICE NG219 first-line for acute gout (preferred over NSAIDs in CKD and elderly)
- Continue until flare fully resolves — usually 5–7 days
- Dose reduction required in CKD (eGFR 10–50: max 500mcg BD; eGFR <10: avoid)
- Drug interactions: statins (rhabdomyolysis risk), ciclosporin (toxicity risk), clarithromycin
- Do NOT exceed maximum dose — colchicine toxicity is potentially fatal (multi-organ failure)
Naproxen 500–750mg BD or Diclofenac 50mg TDS or Indomethacin 50mg TDS (most effective but most GI toxicity). Take at maximum dose immediately — do not start low. Add PPI gastroprotection (omeprazole 20mg OD) if >45 years or any GI risk factor.
- Alternative to colchicine or for patients who cannot tolerate colchicine (GI side effects)
- Avoid in CKD (acute tubular necrosis, fluid retention), heart failure, peptic ulcer disease, anticoagulants
- Indomethacin most effective but highest GI toxicity — use naproxen as preferred NSAID in most patients
- Duration: usually 5–7 days or until flare resolves
Prednisolone 30–40mg OD for 3–5 days — used when colchicine and NSAIDs are both contraindicated or not tolerated. Particularly useful in: CKD (colchicine and NSAIDs both problematic), elderly patients, anticoagulated patients.
- Intra-articular corticosteroid injection: highly effective for a single accessible joint (knee, ankle, wrist) — usually performed by GP with appropriate training or rheumatology
- Oral prednisolone course: tapered over 5–7 days; check blood glucose in diabetics
- Avoid repeated courses — adrenal suppression, osteoporosis, blood glucose dysregulation
- Start 2–4 weeks after the flare fully resolves — never during a flare
- Starting dose: 50–100mg OD — start low; titrate upward every 4 weeks by 50–100mg
- Target: serum urate ≤360 µmol/L (≤300 µmol/L if tophi or frequent flares)
- Always co-prescribe colchicine 500mcg OD as prophylaxis for the first 6 months of ULT — prevents initiation flares
- CKD: start 50mg OD; titrate more slowly; maximum dose depends on eGFR
- HLA-B*5801 screening before allopurinol in Han Chinese, Thai, Korean ancestry — risk of Stevens-Johnson syndrome
- NEVER combine with azathioprine — potentially fatal bone marrow suppression
- Allopurinol is lifelong treatment — do not stop once urate at target (crystals will reform)
- Use when allopurinol is not tolerated (rash, GI intolerance) or contraindicated (allopurinol allergy, transplant with azathioprine)
- Febuxostat 80mg OD (increase to 120mg OD if serum urate remains above target after 4 weeks)
- MHRA 2019 safety update: febuxostat is associated with increased cardiovascular mortality compared to allopurinol in patients with established CVD — use with caution; discuss risk-benefit with patient; allopurinol preferred when both tolerated
- Do NOT use febuxostat with azathioprine or mercaptopurine (same interaction as allopurinol)
- Faster and more potent urate reduction than allopurinol — higher flare risk at initiation; colchicine prophylaxis essential for first 6 months
- Co-prescribe colchicine 500mcg OD prophylaxis for 6 months as with allopurinol
Select patient characteristics — gout treatment recommendation appears below
"Take one tablet two or three times a day during the attack and continue until the pain fully settles — usually about 5–7 days. The most common side effect is diarrhoea — if that happens, reduce to once or twice a day rather than stopping completely. Never take more than the amount prescribed. If you're also on a statin, tell me if you develop severe muscle aching."
Colchicine as prophylaxis (500mcg OD) when initiating ULT is an SCA Task mark — failure to co-prescribe is a clinical error. The allopurinol-initiation flare is predictable and preventable. Also: colchicine + ciclosporin is potentially fatal — always check immunosuppressant list before prescribing.
"Take this at the full dose immediately — this is one situation where you do need the highest dose to dampen the inflammation quickly. Take it with food to protect your stomach. I'm also prescribing a stomach-protecting tablet to take alongside it. Continue until the pain fully settles — usually about a week — then stop."
NSAID + PPI co-prescription in a patient over 45 is a NICE-mandated quality standard — prescribing an NSAID without PPI gastroprotection in this age group is an SCA prescribing error. Always state PPI explicitly when prescribing NSAIDs for gout in the SCA consultation.
"I'm prescribing a short course of steroid tablets to calm this attack because the other options aren't suitable for you. Take them once a day in the morning for 5 days. If you have diabetes, please check your blood sugars more frequently — steroids can temporarily raise them. Don't stop early even if you feel better."
The critical SCA point with prednisolone in gout: septic arthritis must be excluded before prescribing corticosteroids. Corticosteroids in a septic joint will suppress inflammation, mask deterioration, and lead to catastrophic joint destruction. This sequence (septic arthritis exclusion → then prednisolone) must be demonstrated in the SCA to score on the Tasks domain.
"I'm going to start you on allopurinol — but not during this current attack. We'll wait until you're fully better. When we start it, we also prescribe a low-dose anti-inflammatory tablet alongside it for 6 months, because the allopurinol can temporarily trigger a flare at the start. Once your uric acid level is stable and at the target, that risk disappears. This medication is lifelong — if you stop it, the crystals will build up again and the attacks will return. You should not stop it without speaking to me first."
Three mandatory SCA allopurinol points: (1) Never start during an acute flare — wait until fully resolved; (2) Always co-prescribe colchicine prophylaxis for 6 months from initiation; (3) HLA-B*5801 screening before allopurinol in Han Chinese, Thai, or Korean patients. Failure to mention all three is a clinical error. The allopurinol-azathioprine interaction is potentially fatal — always check the drug list before prescribing.
"This medication works in a similar way to allopurinol but is used when allopurinol is not suitable. I need to mention that there was a study showing it might carry a slightly higher risk of heart problems compared to allopurinol — so I'll monitor you carefully while you're on it. Like allopurinol, it can cause a temporary flare when you first start it, so we'll prescribe the anti-inflammatory tablet alongside it for the first six months. And again — this is a lifelong medication."
The MHRA 2019 febuxostat cardiovascular safety update is a mandatory SCA prescribing point. If you prescribe febuxostat without discussing the increased cardiovascular mortality risk (compared to allopurinol) with the patient, and the patient has established CVD, this is a clinical governance and SCA Tasks deduction. Allopurinol is always preferred when both are tolerated.
"I'm suggesting we switch your blood pressure tablet from the water tablet to a different type called losartan. This controls blood pressure in a very similar way, but it also has the added benefit of slightly lowering your uric acid — so it's a double benefit for your gout. I'll check your kidney function and potassium levels about 6 weeks after we switch to make sure everything is settled."
The thiazide-to-losartan switch is a high-yield SCA prescribing task — it demonstrates medication review, knowledge of iatrogenic gout, and NICE NG219 awareness in a single action. Identifying that bendroflumethiazide is the antihypertensive and proposing losartan as a gout-beneficial alternative is a strong Tasks domain score. Always check eGFR and K+ before and after switching.
Stigma and Shame
Gout is culturally portrayed as a disease of gluttons and drinkers — "a rich man's disease." Many patients internalise this narrative, feel deep shame, and blame themselves entirely. This delays presentation, reduces medication adherence, and prevents open discussion.
Explicitly challenge the narrative: gout has strong genetic determinants, and many patients develop it with minimal dietary excess. Normalising the condition as metabolic rather than moral changes the consultation dynamic entirely.
Provide evidence: identical dietary intake produces very different serum urate levels in different individuals due to genetic variation in urate transporters.
"I want to be clear: gout is a metabolic condition with a strong genetic component. It is not simply caused by excess. Many people who develop gout eat no differently from people who don't."Occupational Disability
Acute gout attacks are severely disabling — patients in manual occupations (construction, agriculture, driving, healthcare) may be completely unable to work for days or weeks during a flare. Self-employed patients face financial consequences directly.
For patients with recurrent flares, gout represents a significant loss of earnings and productivity. Framing ULT as "preventing future attacks that stop you working" is a powerful motivational tool for occupationally active patients.
A fit note is appropriate for severe acute gout preventing work. For those with chronic tophaceous gout, disability assessment may be needed.
"How much is this affecting your ability to work? I can provide a fit note for this episode — and the long-term medication should stop these attacks happening at all in the future."Impact on Family and Relationships
Gout attacks are so painful that they affect sleep for the entire household. Partners often become carers during attacks. Recurrent episodes strain relationships — the partner who "told him to cut down on beer years ago" may experience frustration as well as concern.
Alcohol reduction advice needs to be framed sensitively — for many patients, drinking is a social and relationship activity, and cutting down requires family support.
If lifestyle changes are being recommended, involving the partner or family member (with patient consent) in the consultation can significantly improve adherence to dietary and alcohol advice.
"These attacks clearly affect your whole household, not just you. If it would be helpful, we could involve your partner in the conversation about the lifestyle changes — having support at home makes a big difference."Long-Term Medication Acceptance
The idea of taking a daily medication for life is a significant psychological barrier for many patients. This is amplified by the fact that gout attacks come and go — patients feel "well" between attacks and question the need for daily medication when they are asymptomatic.
The key educational message: allopurinol treats the underlying metabolic condition, not the symptoms. The crystal burden in joints and soft tissues continues to build silently between attacks — the attacks are just the visible manifestation of an ongoing process.
Use the analogy of blood pressure treatment: "We treat high blood pressure every day even when you feel fine — because the damage is building up silently. Allopurinol works the same way."
"I understand that taking a daily tablet when you feel fine between attacks seems strange. But the crystals are building up in your joints every day — the attacks are just when they cause enough inflammation to notice. The medication prevents that silent build-up."Understanding of the Condition
Gout has one of the lowest health literacy levels of any common chronic condition. The majority of patients believe: gout is caused entirely by diet; diet change alone will cure it; allopurinol is not needed if they eat well; they can stop allopurinol once they feel better; gout is not a serious disease.
All of these beliefs are inaccurate and will prevent effective management. The educational consultation — explaining the crystal mechanism, the role of genetics, and the rationale for lifelong ULT — is as important as the prescription itself.
Written information (NHS gout leaflet, Arthritis UK) should be provided at every consultation involving ULT initiation.
"I'm going to give you a leaflet about gout that explains everything we've discussed. I'd really like you to read it before your next appointment — it addresses a lot of the questions people have about the medication."Self-Efficacy and Empowerment
Patients who understand the mechanism of their condition and have a clear, achievable treatment plan report significantly better outcomes than those who are simply given a prescription. Shared decision-making in gout — explaining the target serum urate, showing the patient their results, and demonstrating the downward trend — creates engagement and adherence.
Some patients respond well to the "treat-to-target" framing: "Once your uric acid number is below 360, we should stop having these attacks. Let's work together to get to that number."
Patient ownership of the monitoring (understanding what the urate result means) is associated with better long-term adherence than passive medication receipt.
"I'm going to show you your uric acid number today, and tell you where we need to get it to. Once we hit that target, the attacks should stop. Let's work towards that together."1–2 weeks — Acute flare review
Review response to colchicine or NSAID. Has the flare resolved? If not fully resolved: consider whether diagnosis is correct — persistent single hot joint despite treatment raises concern for septic arthritis or reactive arthritis. Assess any side effects from acute treatment. Reinforce that allopurinol will be initiated once fully resolved.
4–6 weeks — ULT initiation + blood results
Serum urate (now accurate, 4–6 weeks post-flare). Renal function, eGFR, FBC before starting allopurinol. HbA1c and lipids if not recently done. Initiate allopurinol 50–100mg OD with colchicine 500mcg OD prophylaxis. Implement thiazide-to-losartan switch if appropriate. Full ULT counselling. Lifestyle review.
4–8 weeks after ULT start — Serum urate + dose titration
Serum urate on treatment. If above target (≤360 µmol/L): increase allopurinol by 50–100mg. Review tolerability (rash, GI upset). Any flares since starting? (Expected — reassure; do not stop allopurinol; colchicine prophylaxis should be preventing them.) Continue colchicine prophylaxis.
6 months — Colchicine prophylaxis review + urate at target?
Is serum urate at target (≤360 µmol/L or ≤300 µmol/L if tophi)? If yes and patient has been flare-free for 3+ months: stop colchicine prophylaxis (6-month minimum). If not at target: dose increase needed. Review alcohol, diet, and hydration. Renal function and FBC check. Review for tophi regression (if present at baseline).
Annual review — Monitoring + CVD risk
Annual serum urate (target ≤360 µmol/L). Annual renal function + FBC + eGFR. Annual alcohol and lifestyle review. Annual cardiovascular risk assessment (QRISK3 — gout is an independent CVD risk factor). If tophi present: assess for regression. If flares have recurred: reconsider ULT adherence and dose adequacy.
Memory rule — Gout Monitoring: URATES
Urate serum level (check 4–6 weeks post-flare; target ≤360 µmol/L or ≤300 with tophi/frequent flares; 4-weekly during titration) · Renal function (eGFR + electrolytes — allopurinol dose must match eGFR; annual monitoring) · Alcohol (AUDIT-C at every consultation; beer most goutogenic) · Tophi (examine at every review — regression confirms ULT working) · Escalation (if urate above target at 12 weeks at maximum tolerated allopurinol dose → consider febuxostat with CVD caveat or rheumatology referral) · Statin/azathioprine interactions (check drug list at every allopurinol prescription)
⚠ Three scenario-specific phrases — use these verbatim
Why safety-netting matters beyond clinical care
- Starting allopurinol during the acute flare — explicit NICE NG219 error
- Not co-prescribing colchicine prophylaxis when starting allopurinol
- Not giving the septic arthritis fever safety-net
- Not giving the allopurinol rash safety-net
- Prescribing allopurinol without checking renal function (eGFR) first
- Not identifying the thiazide diuretic as a modifiable gout risk factor
- Septic arthritis excluded clinically (temperature, systemic features) before treating as gout
- Acute treatment prescribed correctly: colchicine 500mcg BD–TDS or NSAID + PPI
- ULT eligibility determined (≥2 flares/year, tophi, kidney stones) per NICE NG219
- Allopurinol NOT started during flare; 4–6 week follow-up arranged for ULT initiation with colchicine prophylaxis
- Thiazide-to-losartan switch identified if applicable; renal function before allopurinol
- ICE explored — patient's beliefs about diet causing gout, allopurinol-flare concern, expectations about treatment
- Crystal mechanism explained in plain language ("microscopic needles in the joint")
- Diet limitation acknowledged: "diet alone is usually not enough"
- Allopurinol-initiation flare mechanism explained with prophylaxis solution
- Stigma addressed: "gout is not just a disease of excess — there is a strong genetic component"
- Closing question asked: "Is there anything else on your mind?"
Who you are
Mr Rajiv Patel, 54 years old, self-employed plumber. Woke at 3 am with severe pain, redness, and swelling of the right big toe — worst pain of his life; cannot bear the bedsheet touching it. Two similar episodes in the past 18 months, both self-limiting within a week, attributed to "overdoing it at the pub." Takes bendroflumethiazide 2.5mg OD for hypertension (prescribed 3 years ago) and atorvastatin 20mg OD. Drinks approximately 18–20 units of alcohol per week, predominantly beer. Eats red meat 4–5 times per week. Rarely drinks water during the working day. BMI 31. No known kidney disease. No tophi visible but examining ears and hands during examination is expected. BP on examination: 138/84 mmHg.
Hidden agenda
Rajiv is worried the word "gout" means something is seriously wrong with his blood — possibly kidney disease or even cancer. His real fear is also that he will have to stop drinking entirely and change his diet completely, which would affect his social life (pub darts team). He is anxious about taking "yet another tablet" — already on two medications. He will not disclose these concerns unless directly asked. If offered allopurinol, he will express concern that a friend "had a terrible flare when he started allopurinol and came straight off it" — he needs the initiation flare mechanism fully explained before he will accept the prescription. He will also quietly wonder whether the colchicine is safe with his statin — a useful teaching point if the doctor raises it proactively.
Symptoms if asked directly
- Pain: right first MTP joint; 9/10; cannot weight-bear; extreme allodynia (bedsheet)
- Onset: 3 am, woke from sleep, reached maximum intensity within 4 hours
- Previous episodes: 2 in past 18 months (both self-limiting; both attributed to alcohol)
- Systemic: NO fever; not generally unwell; no rigors — temperature will be 37.2°C on examination
- No tophi visible (though ears and hands should be examined — negative in this scenario)
- Alcohol: 18–20 units/week, predominantly beer; large drinking session 2 nights before this episode
- Diet: red meat 4–5 times/week; shellfish occasionally; cola and fruit juice daily
- Hydration: minimal water intake during working day — this connection is new to him
- Medications: bendroflumethiazide 2.5mg OD (hypertension); atorvastatin 20mg OD
- No azathioprine, ciclosporin, or immunosuppressants
- No kidney stones; no haematuria; no known CKD
Lifestyle + bonus details
- Self-employed plumber — cannot work during severe attacks; financial impact is direct and significant
- Drinks beer with workmates after jobs — socially embedded; will resist complete alcohol cessation but is open to reduction if framed practically
- Wife has told him to cut down on beer for years; supportive but frustrated with repeated episodes
- Bonus detail (if doctor asks about caffeine/fizzy drinks): admits to daily cola and fruit juice — has never connected fructose drinks to gout
- Bonus detail (if hydration raised): he barely drinks water during long working days — genuinely receptive when the dehydration-gout link is explained
- Bonus detail (if colchicine + statin interaction raised): will ask if it is safe — an opportunity for the doctor to counsel on the muscle pain monitoring point
Resolution: Rajiv will accept the plan if the doctor: (1) explicitly checks temperature and rules out septic arthritis — explains why this matters; (2) gives colchicine today with clear dosing instructions; (3) acknowledges the severity of the pain empathetically; (4) explains the crystal mechanism ("microscopic needles"); (5) addresses his hidden fear about kidney disease — explains what the blood tests will check; (6) proactively explains the allopurinol-initiation flare mechanism and the colchicine prophylaxis solution before he raises it; (7) clarifies that complete alcohol cessation is not required — reducing beer specifically is the key target; (8) identifies bendroflumethiazide as a modifiable risk and offers the losartan switch; (9) gives the fever safety-net explicitly; (10) confirms allopurinol will NOT start today — follow-up in 4–6 weeks once fully better.
- Hot joint + fever (>38°C) + systemically unwell → same-day aspiration; septic arthritis until proven otherwise
- Immunosuppressed patient + hot joint → same-day aspiration regardless of gout history
- Sepsis with joint involvement (tachycardia, hypotension) → 999
- Rapidly spreading cellulitis / lymphangitis → A&E same day
- Acute urate nephropathy / tumour lysis → urgent nephrology
- First episode without prior diagnosis → bloods + aspiration if uncertain
- Polyarticular gout — first presentation → rheumatology within 2 weeks
- Gout + AKI or worsening CKD → urgent renal function; nephrology
- Severe tophaceous gout with ulceration → wound care + rheumatology
- Known gout, afebrile, immunocompetent → colchicine or NSAID
- Recurrent gout meeting ULT criteria → allopurinol after flare resolves
- Review of established allopurinol → urate + renal function monitoring
| Drug | Monitor | Timing | Action threshold |
|---|---|---|---|
| Allopurinol | Serum urate; eGFR; FBC; skin rash | 4 weeks after each dose change; 3 months; then annually | Urate above target → increase dose by 50–100mg; any rash → STOP immediately; eGFR deterioration → dose reduction; HLA-B*5801 positive → avoid |
| Colchicine (prophylaxis) | Flare frequency; GI tolerability; duration of prophylaxis | Review at 6 months — stop if urate at target + flare-free ≥3 months | Continued flares → ULT dose not yet at target; diarrhoea → reduce to OD; eGFR <10 → contraindicated |
| Febuxostat | Serum urate; LFTs; cardiovascular events | 4 weeks post-start; LFTs at 3 months; annually | LFT >3× ULN → stop; cardiovascular event → reassess vs allopurinol switch; annual CVD risk review |
| Losartan switch | BP; eGFR; serum K+; serum urate | 4–6 weeks after switch; then 6-monthly | K+ >5.5 mmol/L → dose reduction; BP not controlled → titrate to 100mg; urate → expect 15–20% reduction |